arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Neumora Therapeutics, Inc.

NMRA

$0.73 ▼ -0.04 (-5.16%) at close

19 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Neumora Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $135.2M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -43.3% →

FCF / Share $-0.21 ↗

Trailing P/E —

Price / Book 3.0x

FCF Yield —

Debt / Equity 1.19

info Valuation on last close. End-of-day price, Sep 23, 2026.

19-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-53.46M

↑ +21.4% —

FCF / Share Free cash flow per share

$-0.21

↑ +34.1% —

Long-Term Debt Long-term obligations

$52.91M

— -0.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	30.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	28.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	5.4% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	22.2% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	10.8% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-23.5% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-825.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	60.5% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	71.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	72.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	95.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-7.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	21.4% Good ↑ Good Improving Year-over-year change in net income	21.4% Good ↑ Good Improving Year-over-year change in net income	-1.1% Weak ↑ Weak Improving Year-over-year change in net income	-26.6% Weak ↓ Weak Declining Year-over-year change in net income	-26.6% Weak ↓ Weak Declining Year-over-year change in net income	-26.6% Weak ↓ Weak Declining Year-over-year change in net income	45.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-50.8% Weak ↑ Weak Improving Year-over-year change in net income	-50.8% Weak ↑ Weak Improving Year-over-year change in net income	-50.8% Weak ↑ Weak Improving Year-over-year change in net income	-286.3% Weak Weak Year-over-year change in net income	17.2% Good Good Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	34.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	29.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	—	-37.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	8.2% Fair ↓ Fair Declining Year-over-year change in free cash flow	-35.4% Weak ↓ Weak Declining Year-over-year change in free cash flow	—	79.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	65.7% Excellent Excellent Year-over-year change in free cash flow	75.9% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.47x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.34x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-43.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-36.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-19.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	6.5% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	6.5% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	5.4% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	5.7% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-33.7% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-34.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-30.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-32.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-27.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-19.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-13.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-23.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—	—	—
Return on Common Equity (%) (%)	-120.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-901%)	-75.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-604%)	-57.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-482%)	-51.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-443%)	-37.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-348%)	-29.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-298%)	-20.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-237%)	-16.7% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-212%)	-14.1% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-194%)	-12.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-184%)	-23.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-255%)	-6.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-146%)	6.9% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-54%)	7.5% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-50%)	6.3% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-58%)	10.2% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-32%)	—	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Debt to Equity (x)	1.19x Caution ↑ Caution Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+98%)	0.75x Fair ↑ Fair Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+25%)	0.52x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-13%)	0.15x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-75%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Interest Coverage (x)	-29.59x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-36.81x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-28.72x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-77.24x Weak Weak Operating income divided by interest expense Optimal: > 5x	-176.03x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Debt (USD)	$-63.92M	$-94.11M	$-128.00M	$-109.51M	—	$-126.86M	$-142.15M	$-275.71M	$-150.68M	$-182.93M	$-374.04M	$-412.28M	$-204.22M	$-210.87M	$-240.94M	$-252.51M	—	—	—
Debt / EBITDA (x)	-1.25x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.00x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.93x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.34x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Basic EPS, GAAP (USD)	$-0.23	$-0.30	$-0.35	$-0.35	$-0.33	$-0.42	$-0.37	$-0.45	$-0.37	$-0.34	$-0.04	$-1.14	$-1.28	$-1.22	$-0.98	$-1.06	—	—	—
Free Cash Flow per Share (USD)	$-0.21	$-0.26	—	$-0.29	$-0.32	$-0.37	—	$-0.21	$-0.35	$-0.27	—	$-1.02	$-1.03	$-1.13	—	—	—	—	—
Book Value per Share (USD)	$0.24	$0.39	$0.60	$0.82	$1.13	$1.41	$1.78	$2.01	$2.40	$2.69	$2.95	$10.98	$-17.05	$-16.32	—	$-15.26	—	—	—
Tangible Book Value per Share (USD)	$0.24	$0.39	$0.60	$0.82	$1.13	$1.41	$1.78	$2.01	$2.40	$2.69	$2.95	$10.98	$-17.05	$-16.32	—	$-15.26	—	—	—
Basic Weighted Avg Shares (shares)	185.16M	179.87M	—	161.84M	161.69M	161.45M	—	159.58M	158.98M	157.94M	—	46.69M	30.12M	29.28M	—	27.65M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$97.10M	$123.32M	$158.09M	$151.24M	—	$226.48M	$284.17M	—	—	$418.18M	$453.17M	—	—	—	—	—	—	—	—
LT Debt (USD)	$52.91M	$52.96M	$54.53M	$19.56M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total Equity (USD)	$44.52M	$70.68M	$103.87M	$132.16M	$182.88M	$228.36M	$287.06M	$320.74M	$381.26M	$424.54M	$469.08M	$512.69M	$-513.54M	$-477.92M	$-446.85M	$-422.00M	$-394.71M	$-325.22M	$-325.22M

📋 What is driving earnings? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Depreciation Expense (USD)	$7.00K	$8.00K	$9.00K	$23.00K	$19.00K	$157.00K	$157.00K	$156.00K	$160.00K	$158.00K	$166.00K	$173.00K	$171.00K	$158.00K	$147.00K	—	—	—	—
Net Income, GAAP (USD)	$-53.46M	$-53.46M	$-59.45M	$-67.99M	$-67.99M	$-67.99M	$-58.82M	$-53.72M	$-53.72M	$-53.72M	$-108.73M	$-35.62M	$-35.62M	$-35.62M	$-28.15M	$-43.04M	—	—	—
Operating Cash Flow (USD)	$-39.53M	$-46.40M	$-47.95M	$-46.63M	$-52.40M	$-59.45M	$-50.34M	$-33.48M	$-56.16M	$-42.95M	$-51.44M	$-47.77M	$-31.02M	$-33.04M	$-30.37M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 19 quarters

Neumora Therapeutics, Inc.

Analytical Summary

19-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NMRA with peers